Psychogenic parkinsonism: A combination of clinical, electrophysical, and [123I]-FP-CIT SPECT scan explorations improves diagnostic accuracy

Movement Disorders

Volumn 21, Issue 3, 2006, Pages 310-317

  Benaderette, Sandrine ^a,b   Fregonara, Paolo Zanotti ^a   Apartis, Emmanuelle ^a   Nguyen, Charles ^a   Trocello, Jean Marc ^a   Remy, Philippe ^b,c   Devaux, Jean Yves ^a   Askienazy, Serge ^a   Vidailhet, Marie ^a,d  

^a HÔPITAL SAINT ANTOINE   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c DIF   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Ioflupane SPECT scan (DaTSCAN); Neurophysiology; Parkinson's disease; Psychogenic movement disorders; Psychogenic parkinsonism; Psychogenic tremor

Indexed keywords

6 FLUORODOPA F 18; ANTIPARKINSON AGENT; BROMOCRIPTINE; IODINE 123; LEVODOPA; PIRIBEDIL; ROPINIROLE; TRIHEXYPHENIDYL;

ADULT; ARTICLE; AUTONOMIC DENERVATION; BRAIN ELECTROPHYSIOLOGY; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DISEASE CLASSIFICATION; DOPAMINERGIC SYSTEM; DRUG DOSE REGIMEN; ELECTROMYOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MALE; MENTAL DISEASE; PARKINSON DISEASE; PARKINSONISM; PATIENT REFERRAL; PRIORITY JOURNAL; PSYCHOGENESIS; RECORDING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREMOR;

ADULT; ANXIETY; BRAIN; CEREBROVASCULAR CIRCULATION; DEPRESSION; DIAGNOSIS, DIFFERENTIAL; ELECTROMYOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; PARKINSON DISEASE, SECONDARY; PSYCHOTHERAPY; RADIOPHARMACEUTICALS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 33645550540     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20720     Document Type: Article

References (25)

1. Miyasaki JM, Sa DS, Galvez-Jimenez N, Lang AE. Psychogenic movement disorders. Can J Neurol Sci 2003;30(Suppl. 1):S94-S100.
2. Lang AE, Koller WC, Fahn S. Psychogenic parkinsonism. Arch Neurol 1995;52:802-810.
3. Factor SA, Podskalny GD, Molho ES. Psychogenic movement disorders: frequency, clinical profile, and characteristics. J Neurol Neurosurg Psychiatry 1995;59:406-412.
4. Kim YJ, Pakiam AS, Lang AE. Historical and clinical features of psychogenic tremor: a review of 70 cases. Can J Neurol Sci 1999;26:190-195.
5. Deuschl G, Koster B, Lucking CH, Scheidt C. Diagnostic and pathophysiological aspects of psychogenic tremors. Mov Disord 1998;13:294-302.
6. McAuley JH, Rothwell JC, Marsden CD, Findley LJ. Electrophysiological aids in distinguishing organic from psychogenic tremor. Neurology 1998;50:1882-1884.
7. Brown P, Thompson PD. Electrophysiological aids to the diagnosis of psychogenic jerks, spasms, and tremor. Mov Disord 2001; 16:595-599.
8. Milanov I. Electromyographic differentiation of tremors. Clin Neurophysiol 2001;112:1626-1632.
9. McAuley J, Rothwell J. Identification of psychogenic, dystonic, and other organic tremors by a coherence entrainment test. Mov Disord 2004;19:253-267.
10. Zeuner KE, Molloy FM, Shoge RO, Goldstein SR, Dambrosia JM, Hallett M. Accelerometry to distinguish psychogenic from essential or parkinsonian tremor. Neurology 2003;61:548-550.
11. Feinstein A, Stergiopoulos V, Fine J, Lang AE. Psychiatric outcome in patients with a psychogenic movement disorder: a prospective study. Neuropsychiatry Neuropsychol Behav Neurol 2001;14:169-176.
12. 123I]-FP-CIT study group. Mov Disord 2000;15:503-510.
13. Tolosa E, Coelho M, Gallardo M. DAT imaging in drug-induced and psychogenic parkinsonism. Mov Disord 2003;18(Suppl. 7): S28-S33.
14. Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord 2003;18:1415-1423.
15. Daniel SE, Lees AJ. Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm 1993;39(Suppl.): 165-172.
16. Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder Society on Tremor: Ad Hoc Scientific Committee. Mov Disord 1998;13(Suppl. 3):2-23.
17. Fahn S, Williams DT. Psychogenic dystonia. Adv Neurol 1988; 50:431-455.
18. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54:93-101
19. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
20. 123I] β-CIT and single-photon emission computed tomographic imaging versus clinical evaluation in parkinsonian syndrome. Arch Neurol 2004;61:1224-1229.
21. 123I]-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 2004;19:1175-1182.
22. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
23. Thobois S, Guillouet S, Broussolle E. Contributions of PET and SPECT to the understanding of the pathology of Parkinson's disease. Neurophysiol Clin 2001;31:321-340.
24. Marek KL, Jennings DL, Seibyl JP. Long-term follow-up of patients with scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA study. Neurology 2005;64(Suppl. 1):A274.
25. Ranawaya R, Riley D, Lang A. Psychogenic dyskinesias in patients with organic movement disorders. Mov Disord 1990;5:127-133.